Accès ouvert
2025
article
OpenAlex
Daniel S. Hsia, Naji Younes, Alokananda Ghosh, Erin J. Kazemi et autres
OBJECTIVE: To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin. RESEARCH DESIGN AND METHODS: Intention-to-treat (ITT) (N …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Kristina M. Utzschneider, Mark Tripputi, Nicole M. Butera, Andrea Mari et autres
OBJECTIVE: To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell …
us, it
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jeffrey S. Gonzalez, Ionut Bebu, Heidi Krause‐Steinrauf, Claire J. Hoogendoorn et autres
OBJECTIVE: We evaluated whether adding basal insulin to metformin in adults with early type 2 diabetes mellitus (T2DM) would increase emotional distress relative to other treatments. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) of …
us, au
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jennifer B. Green, Brendan M. Everett, Alokananda Ghosh, Naji Younes et autres
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by …
us, pe
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
W. Timothy Garvey, Robert M. Cohen, Nicole M. Butera, Erin J. Kazemi et autres
OBJECTIVE: To describe the individual and joint associations of baseline factors with glycemia, and also with differential effectiveness of medications added to metformin. RESEARCH DESIGN AND METHODS: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants (with type 2 diabetes …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mary Ann Banerji, John B. Buse, Naji Younes, Heidi Krause‐Steinrauf et autres
OBJECTIVE: We report mortality outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) among people with type 2 diabetes diagnosed within 10 years and no recent history of cardiovascular events or cancer. RESEARCH DESIGN AND METHODS: Overall mortality …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Andrea Cherrington, Ionut Bebu, Heidi Krause‐Steinrauf, Claire J. Hoogendoorn et autres
OBJECTIVE: To evaluate whether baseline levels of depressive symptoms and diabetes-specific distress are associated with glycemic control in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), a large randomized controlled trial comparing the metabolic effects of four common glucose-lowering medications …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Claire J. Hoogendoorn, Heidi Krause‐Steinrauf, Diane Uschner, Hui Wen et autres
OBJECTIVE: We examined longitudinal associations between emotional distress (specifically, depressive symptoms and diabetes distress) and medication adherence in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), a large randomized controlled trial comparing four glucose-lowering medications added to metformin in adults …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
M. Sue Kirkman, Mark Tripputi, Heidi Krause‐Steinrauf, Ionut Bebu et autres
OBJECTIVE: In Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (5,047 participants, mean follow-up 5.0 years), differences in glycemic control were demonstrated over time among four randomized therapies added to metformin. Weight gain and hypoglycemia are also important outcomes for …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Andrea Cherrington, Mark Tripputi, Naji Younes, William H. Herman et autres
OBJECTIVE: Diabetes is associated with reduced health-related quality of life (HRQoL). Information on the relationship between HRQoL and glucose-lowering medications in recently diagnosed type 2 diabetes (T2D) is limited. We assessed changes in HRQoL in participants with T2D receiving metformin plus one …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Kristina M. Utzschneider, Naji Younes, Nicole M. Butera, Ashok Balasubramanyam et autres
OBJECTIVE: To compare the effects of insulin sensitivity and β-cell function over time on HbA1c and durability of glycemic control in response to dual therapy. RESEARCH DESIGN AND METHODS: GRADE participants were randomized to glimepiride (n = 1,254), liraglutide (n = 1,262), …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Priscilla Hollander, Heidi Krause‐Steinrauf, Nicole M. Butera, Erin J. Kazemi et autres
OBJECTIVE: To describe rescue insulin use and associated factors in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: GRADE participants (type 2 diabetes duration <10 years, baseline A1C 6.8%-8.5% on metformin monotherapy, N = 5,047) …
us
(code pays fourni par la source)